Claims in this piece are observable and methodological — no client or benchmark data used.
For a contract research organisation, the hardest part of being discoverable is not a lack of expertise — it’s that so much of the expertise is confidential. Your strongest proof is specific past studies, named sponsors, and outcomes you cannot publish. So when a sponsor’s team researches CROs before an RFP — increasingly with an AI assistant — what they can actually find about you often collapses into the same generic language every CRO uses: “full-service,” “global,” “therapeutic expertise across multiple areas.” The parent article, AI Visibility for CROs: Winning Trust Before the RFP, sets out why that pre-RFP legibility matters and the four things a sponsor’s early research tries to establish. This piece is narrower and more practical: how do you actually demonstrate genuine expertise online without breaching a single confidence?
The principle: describe the shape of your experience, not its confidential specifics
The resolution to the confidentiality problem is a distinction worth holding onto. You cannot disclose which sponsor, which molecule, which trial. But you can describe, accurately and without identifying anyone, the shape of your genuine experience: the therapeutic areas where you have real depth, the study types and phases you run, the regulatory pathways and regions you operate across, and how you actually work. None of that requires naming a client or exposing a study. All of it gives an outside researcher — human or AI — something specific to establish, instead of a generic claim to skip past.
The rest of this article is what that looks like in practice.
Six ways to make genuine CRO expertise legible
1. State therapeutic-area depth specifically, not as a list. “Experience across multiple therapeutic areas” establishes nothing. Naming the areas where you have genuine, repeated depth — and describing what running trials in that area actually involves for you — signals real specialisation. A CRO that can speak specifically about, say, the recruitment and endpoint challenges of a particular indication reads as expert; one that lists twelve therapeutic areas equally reads as generalist.
2. Describe study types and phases you genuinely run. Be specific about the work you actually do — early-phase, complex late-phase, adaptive designs, particular endpoint types, patient populations that are hard to recruit. A sponsor researching for a specific kind of study is trying to match a requirement; specificity is what lets them (and an AI) make the match.
3. Make regulatory and geographic reach explicit. Which regulatory pathways and regions is your experience genuinely built on? Stating this clearly — rather than implying it through “global reach” — lets a sponsor confirm you fit the regulatory and operational footprint their trial needs.
4. Explain how you work, not just what you offer. Your methodology, your approach to data quality, your operational model, how you handle the parts of a trial that go wrong — this is where genuine expertise shows without touching confidential detail. Describing how you run a study demonstrates depth that a services list never can.
5. Publish genuine, non-confidential thought leadership. Your people’s real expertise — on a therapeutic area, a regulatory shift, an operational challenge — can be shared publicly without any client detail. Substantive, specific writing on the things you genuinely know is establishable evidence of expertise. Generic “the future of clinical trials” content is not; specific, experienced perspective is. This is the safest and most scalable way to demonstrate depth, because it draws on knowledge, not on any particular study.
6. Use anonymised experience only with genuine care. You can, in principle, describe the kind of programme you’ve run — “a first-in-human study in [area] requiring [specific capability]” — without naming a sponsor or molecule. But treat this as the most cautious item on the list, not the easiest. Two tests must both pass: it must clear your actual confidentiality obligations (a CDA or MSA can be breached by detail specific enough to identify a study, even with no name attached), and it must be genuinely representative, not embellished. If an anonymised example can’t clear both tests, leave it out — the thought-leadership route above achieves the same signal without the risk.
The line you must not cross
Everything above rests on one rule that this piece shares with the whole of Emerivo’s approach: make genuine expertise legible; never manufacture or overstate it. It is tempting, in a competitive field, to imply depth in an area you’ve touched only once, or to dress up modest experience as specialism. Don’t. In clinical research, an inflated claim of expertise fails at exactly the moment it matters most — when a sponsor moves from early research to real evaluation and due diligence. The goal is not to sound more expert than you are; it is to make the expertise you genuinely have easy for an outsider to establish. Legibility helps only when what’s made legible is true.
Could a sponsor’s team, reading only our public presence, tell the difference between the therapeutic areas where we have genuine depth and the ones we merely list — or do we present them all as equal?
A check you can run
Take the therapeutic area where you are genuinely strongest, and read your own website as a sponsor’s clinical lead who has never heard of you would. Can they establish, from public pages alone, that you have real depth there specifically — the study types, the regulatory context, the way you work — without insider knowledge? Then ask ChatGPT, Gemini, Perplexity, Claude and Copilot a sponsor-style question about CROs in that area, and see whether the assistants can articulate your genuine depth or fall back on generic description. Where they can’t, that’s where your real expertise isn’t yet legible — and the six approaches above are where to start. Results vary by platform and time, so treat it as observation, not proof.
The takeaway
A CRO’s confidentiality is real, but it is not a reason to be invisible. The specifics of your best work stay private; the shape of your genuine expertise — where you have real depth, what you run, how you work, the regulatory ground you stand on — can and should be made clear, specific, and consistent online. That is how a sponsor, or the AI assistant helping them, establishes that you belong in the consideration set before the RFP is ever written. The discipline is simple to state and easy to get wrong: demonstrate what you genuinely are, in specific terms, and never more than that.
Emerivo helps pharmaceutical manufacturing and research organisations — TPMs, CMOs, CDMOs and CROs — make genuine capability and expertise legible to buyers, sponsors, and AI assistants. The AI Discovery Audit™ examines what AI assistants can currently establish about your organisation against realistic sponsor and buyer questions — diagnostic, not a promise of rankings or recommendations. Read the parent cornerstone: AI Visibility for CROs: Winning Trust Before the RFP.
Frequently asked questions
By describing the shape of your experience — therapeutic-area depth, study types, phases, regulatory pathways, and how you work — accurately and without naming sponsors, molecules, or specific trials. The confidential specifics stay private; the establishable substance becomes clear.
It can be, so treat it as the most cautious option. It must clear two tests: it can’t breach your confidentiality obligations (a CDA/MSA can be breached by detail specific enough to identify a study, even without names), and it must be genuinely representative, not embellished. If in doubt, use thought leadership instead — it demonstrates the same depth without the risk.
Not on its own — RFP wins turn on the proposal, the team, and evaluation. But substantive, specific expertise published online helps a sponsor establish, before the RFP, that you belong on the shortlist. It affects consideration, not the award.
No — no credible provider can promise that. Making genuine expertise legible improves how accurately an outsider can establish your depth; it does not purchase a recommendation.